…Awareness… the implementation of medical cannabis and psychedelics… adjunct to standard therapy… advanced metastatic…
Published in the Journal, Drug Science, Policy and Law, [with authors Rayyan Zafar and David Nutt (who performed the first MRI of a human brain under the influence of LSD)], from Imperial College London, Centre for Psychedelic Research and Neuropsychopharmacology, UK: this case highlights the plausible therapeutic role of such plant-based medicines in oncology treatment and documents pharmacological parameters in which clinical efficacy was achieved in this patient. Sensational as this sounds, it’s important not to get carried away by a single case study or to jump to conclusions about whether or not weed and psychedelics were responsible for the patient’s remarkable recovery. Being an observational study, the report does not provide any biomedical analysis of the woman’s disease progression or treatment protocol.
Here, we report a case of a patient with stage IV metastatic breast cancer that underwent successful remission following a combination of targeted chemotherapy including pertuzumab, trastuzumab and DOCEtaxel with a ketogenic diet, and adjunctive treatment with self-administered medical cannabis and psychedelics. A 49-year-old woman with advanced metastatic breast cancer has successfully halted the spread of the disease with chemotherapy alongside cannabis oil and magic mushrooms, according to a new case report. After halting her conventional cancer treatment, the patient remained disease-free for 18 months while using only cannabis and psilocybin, but experienced a recurrence when she stopped self-medicating with these psychoactive drugs… “This brings up the possibility that withdrawal of the cannabinoid and psychedelic therapies may have contributed to the return of the cancer,” write the study authors… a recurrence of disease was noted at 18 months follow up. Over these 18 months the cannabis regimen was titrated down to 60% of the initial protocol. This was subsequently increased to the initial dosing protocol following detection of recurrent disease and this titration occurred over a 10-month period where it remained stable. 16 months following the detection of recurrence of disease, favourable results were observed in the patient with evidence of receding cancer progression. Over the last 15 years there has been a considerable body of in-vitro and in-vivo evidence supporting the anti-neoplastic properties of cannabinoids and more recently psychedelics.
Original Article (Drug Science and ILF Science):
Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer & Cannabis and psilocybin may have helped this woman’s breast cancer treatment
Artwork Fair Use: Public domain